262 related articles for article (PubMed ID: 26423795)
1. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
[TBL] [Abstract][Full Text] [Related]
4. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
[TBL] [Abstract][Full Text] [Related]
5. Phase I study assessing the mass balance, pharmacokinetics, and excretion of [
Zhou X; Sedarati F; Faller DV; Zhao D; Faessel HM; Chowdhury S; Bolleddula J; Li Y; Venkatakrishnan K; Papai Z
Invest New Drugs; 2021 Apr; 39(2):488-498. PubMed ID: 33089874
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
[TBL] [Abstract][Full Text] [Related]
7. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Zhou X; Vaishampayan U; Mahalingam D; Harvey RD; Chung KY; Sedarati F; Dong C; Faller DV; Venkatakrishnan K; Gupta N
Invest New Drugs; 2022 Oct; 40(5):1042-1050. PubMed ID: 35932388
[TBL] [Abstract][Full Text] [Related]
9. A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors.
Yamamoto N; Shimizu T; Yonemori K; Kitano S; Kondo S; Iwasa S; Koyama T; Sudo K; Sato J; Tamura K; Tomomatsu J; Ono M; Fukuda N; Takahashi S
Invest New Drugs; 2021 Aug; 39(4):1036-1046. PubMed ID: 33560503
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and Disposition of [
Bolleddula J; Chen H; Cohen L; Zhou X; Pusalkar S; Berger A; Sedarati F; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2022 Jul; 50(7):989-997. PubMed ID: 35504658
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
12. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
[TBL] [Abstract][Full Text] [Related]
13. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.
Wei LY; Wu ZX; Yang Y; Zhao M; Ma XY; Li JS; Yang DH; Chen ZS; Fan YF
Exp Cell Res; 2020 Mar; 388(2):111858. PubMed ID: 31972220
[TBL] [Abstract][Full Text] [Related]
15. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
16. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
Flores-Martínez YA; Le-Trilling VTK; Trilling M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
[TBL] [Abstract][Full Text] [Related]
17. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
[TBL] [Abstract][Full Text] [Related]
18. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Swords RT; Coutre S; Maris MB; Zeidner JF; Foran JM; Cruz J; Erba HP; Berdeja JG; Tam W; Vardhanabhuti S; Pawlikowska-Dobler I; Faessel HM; Dash AB; Sedarati F; Dezube BJ; Faller DV; Savona MR
Blood; 2018 Mar; 131(13):1415-1424. PubMed ID: 29348128
[TBL] [Abstract][Full Text] [Related]
19. Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.
Kuboki Y; Shimizu T; Yonemori K; Kojima T; Kondo S; Koganemaru S; Iwasa S; Harano K; Koyama T; Lu V; Zhou X; Niu H; Yanai T; Garcia-Ribas I; Doi T; Yamamoto N
Cancer Res Commun; 2022 Nov; 2(11):1426-1435. PubMed ID: 36970056
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
